Pharma BD Deal Intelligence

Novartis AG / Alteogen

2026 · Licensing/Option · $3.2B · Complete

On September 2, 2026, Alteogen entered an option and license agreement with Novartis covering development and commercialization of subcutaneous formulations of multiple Novartis products using ALT-B4 (berahyaluronidase alfa), Alteogen's recombinant human hyaluronidase built on its Hybrozyme platform. Novartis receives multiple options to obtain exclusive rights on a product-by-product basis. The agreement is worth up to US$3.22 billion in option exercise fees and development and commercial milestones if all options are exercised, plus royalties on net sales. The upfront payment was not disclosed. NOTE: ingested at pending_review by bd-enrichment 2026-09-07.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novartis AG deals